Visit Corning at SLAS 2026 to see the latest solutions for drug discovery and lab automation with a focus on 3D cell culture. We invite you to learn more about our solutions in our exhibit, including:
| Title | Time |
| Course: Mastering 3D Cell Culture: A Practical Toolbox from Research to High Throughput | 8:30 AM – 4:30 PM |
Speakers:
| |
To 3D or not to 3D – this is a question at the forefront for most people in discovery programs. With the passing of the FDA Modernization Act 2.0, there is a greater interest in the community around the use of physiologically relevant in vitro models as New Approach Methods (NAM) for the use of IND enabling submissions to the FDA. This workshop is designed to help participants understand the nuts and bolts of setting up 3D physiologically relevant models, will allow participants to understand not only the utility of these models in answering a specific biological question but also to understand the practical importance of the various stages of assay development, automation compatibility, high content imaging and data analysis. Without a robust, scalable and reproducibly functioning assay there is no actionable data. At the end of this workshop, participants should be able to leave with the confidence of understanding the importance of robust and scalable assay development for 3D models and how that will allow them to position and prioritize pre-clinical candidates in their discovery programs. | |
| Title | Presented By | Time | Location |
| De-risking CNS Drug Discovery with AI-Powered Human Brain Organoids | Maya Gosztyla, Ph.D., Co-Founder and Chief Scientific Officer, Brainstorm Therapeutics | 4:00 - 4:20 PM | Exhibition Hall: Solutions Spotlight Theater |
| BrainStorm Therapeutics is harnessing patient iPSC-derived brain organoids to model complex neurological diseases with unprecedented accuracy. Traditional animal and cell models often fail to capture the intricacies of human brain biology, limiting therapeutic success. Our platform generates 3D brain organoids from patient iPSCs that faithfully recapitulate disease-relevant cell types, neural circuits, and phenotypes, including dopaminergic neuron loss and lipid metabolism defects seen in Parkinson’s disease. These models serve as a foundation for high-content screening, transcriptomic profiling, and functional analysis, enabling us to uncover both generalizable and mutation-specific disease mechanisms. By layering in AI tools trained on multimodal biological data, we enhance our ability to map dysregulated pathways and prioritize therapeutic targets. Our “clinical trial in a dish” approach supports more predictive and patient-relevant drug testing, reducing cost and risk in early-stage R&D. We are extending this organoid-based platform to additional brain disorders like Rett Syndrome and CDKL5 Deficiency Disorder, with the goal of delivering precision treatments rooted in human biology. | |||
Axygen® PCR Microplates
Learn More: Axygen® PCR MicroplatesOur new Axygen PCR microplates have an industry standard footprint enabling the compatibility with automated liquid handlers and most thermal cyclers. Each microplate is engineered to stay warp-free, provide precise positioning for automation, and deliver pressure resistance without distortion.
Organoid Counting Software for the Corning Cell Counter
Learn More: Organoid Counting Software for the Corning Cell CounterCorning's automated cell counting software for the Corning Cell Counter provides 3D capabilities for automated cell counting of organoids.
Automation Tips
Learn More: Automation TipsCorning is your source of high quality automation tips for automated liquid handling equipment.
Microplates
Learn More: MicroplatesCorning and Falcon® microplates are ideal for drug discovery applications, including assay prep, assay development, and HTS and automation.
